It's not just how much money that is being raised by psychedelic drug companies. It's HOW they are doing it.
It's not just how much money that is being raised by psychedelic drug companies. It's HOW they are doing it.
Mind Cure has upsized its bought deal financing by DOUBLE to CAD$20 million.
Mind Cure announces a CAD$10 million bought deal financing at a unit price of CAD$0.60. Proceeds will be directed toward product research development and related tech initiatives like its iSTRYM digital therapeutics platform.
The U.S. election has become a major political circus. With investors distracted and the media focused elsewhere, psychedelic stocks are temporarily at low tide.
MindCure signs LOI to make a strategic investment in ATMA, a psychedelics-assisted therapy center in Calgary, Alberta.
Psychedelic Stock Watch connects the dots regarding Mind Cure's clinic launch and latest product development news.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now